Photo: Depositphotos
Dec 21, 2024, 07:31
Update on U.S. regulatory review of subcutaneous amivantamab for EGFR + lung cancer
Estela Rodriguez shared a post on X:
“This is disappointing.
I thought we would have amivantamab subq formulation for EGFR + lung cancer for Christmas, which could make drug delivery easier, but FDA Oncology says not yet.
Update on U.S. regulatory review of subcutaneous amivantamab.
For more information click here.”
Estela (Estelamari) Rodriguez is Associate Director of Community Outreach and Co-Lead of Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine. She is board certified in medical oncology and hematology. She has a special interest in the early detection of lung cancer and increasing access to clinical trials.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 1, 2025, 19:09
Apr 1, 2025, 18:48
Apr 1, 2025, 18:37
Apr 1, 2025, 18:26
Apr 1, 2025, 18:22